Bod Science (ASX:BOD) - Hisse Senedi Fiyatı, Haberler ve Analizler

BOD Stoklara Genel Bakış

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States.

Şirket hakkında

BOD temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Earnings have declined by 4.2% per year over past 5 years

Does not have a meaningful market cap (A$4M)

Negative shareholders equity

Shares are highly illiquid

+ 2 daha fazla risk

Bod Science Limited Rakipler

Cann Global

ASX:CGB

AU$5.4m

Avecho Biotechnology

ASX:AVE

AU$9.5m

Epsilon Healthcare

ASX:EPN

AU$7.2m

Wellfully

ASX:WFL

AU$1.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bod Science
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.024
52 Haftanın En Yüksek Seviyesi	AU$0.13
52 Haftanın En Düşük Seviyesi	AU$0.024
Beta	1.45
11 Aylık Değişim	0%
3 Aylık Değişim	-7.69%
1 Yıllık Değişim	-65.22%
33 Yıllık Değişim	-94.95%
5 Yıllık Değişim	-95.10%
Halka arzdan bu yana değişim	-91.72%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	BOD	AU Pharmaceuticals	AU Pazar
7D	0%	-2.3%	-1.1%
1Y	-65.2%	61.9%	16.1%

Getiri vs. Endüstri: BOD underperformed the Australian Pharmaceuticals industry which returned 61.8% over the past year.

Getiri vs Piyasa: BOD underperformed the Australian Market which returned 9.6% over the past year.

Fiyat Oynaklığı

Is BOD's price volatile compared to industry and market?
BOD volatility
BOD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: BOD has not had significant price volatility in the past 3 months.

Zaman İçindeki Volatilite: Insufficient data to determine BOD's volatility change over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	n/a	Jo Patterson	bodscience.com

Bod Science Limited Temel Bilgiler Özeti

Bod Science'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BOD temel i̇stati̇sti̇kler
Piyasa değeri	AU$4.26m
Kazançlar(TTM)	-AU$7.95m
Gelir(TTM)	AU$3.32m

1.3x

P/S Oranı

-0.5x

F/K Oranı

BOD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BOD gelir tablosu (TTM)
Gelir	AU$3.32m
Gelir Maliyeti	AU$1.05m
Brüt Kâr	AU$2.27m
Diğer Giderler	AU$10.22m
Kazançlar	-AU$7.95m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.045
Brüt Marj	68.40%
Net Kâr Marjı	-239.47%
Borç/Özkaynak Oranı	-136.9%

BOD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BOD Stoklara Genel Bakış

Ödüller

Risk Analizi

Bod Science Limited Rakipler

ASX:CGB

AU$5.4m

ASX:AVE

AU$9.5m

ASX:EPN

AU$7.2m

ASX:WFL

AU$1.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Less than half of directors are independent

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Full year 2022 earnings released: AU$0.051 loss per share (vs AU$0.043 loss in FY 2021)

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Less than half of directors are independent

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn Situation

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth Plans

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

Why Bod Australia's (ASX:BDA) CEO Pay Matters

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.61

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.53

New 90-day high: AU$0.40

New 90-day high - AU$0.30

Earnings released

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Bod Science Limited Temel Bilgiler Özeti

1.3x

-0.5x

Kazanç ve Gelir